{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:02:16Z","timestamp":1771556536195,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. Additionally, it can cause central nervous system (CNS) symptoms, which include hoarseness, ataxic tremor, ataxic gait, nystagmus, dysmetria, and dysdiadochokinesia. In this article, we present the first case report of dysphonia, absent of CNS symptoms, induced by high-dose cytarabine (HiDAC) in a patient with acute myeloid leukemia. The patient\u2019s voice began to change 3\u00a0days following the first cycle of HiDAC chemotherapy, and dysphonia recurred upon the reintroduction of HiDAC. To rule out other potential causes, a thorough examination and detailed medical history review were conducted, excluding factors such as vocal abuse, infection, effects of other medications, and underlying diseases as contributors to the dysphonia. The patient was diagnosed with HiDAC-induced dysphonia. This toxic effect was self-limiting, and the patient recovered in 10\u201315\u00a0days. Chemotherapy-induced dysphonia is a rarely reported and easily overlooked side effect. This adverse reaction is typically temporary and non-life-threatening; however, it substantially diminishes quality of life and may occasionally necessitate the discontinuation or postponement of chemotherapy. Physicians should be aware of this complication when administering chemotherapeutic agents.<\/jats:p>","DOI":"10.3389\/fphar.2025.1518298","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:40:46Z","timestamp":1737960046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Dysphonia associated with high-dose cytarabine therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Ling","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000411637","article-title":"Neurotoxicity of high-dose cytosine arabinoside","volume":"29","author":"Barnett","year":"1985","journal-title":"Prog. Exp. Tumor Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1179\/joc.2004.16.6.595","article-title":"Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy","volume":"16","author":"Berretta","year":"2004","journal-title":"J. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1017\/s002221510014085x","article-title":"Vocal fold palsy following vinca alkaloid treatment","volume":"112","author":"Burns","year":"1998","journal-title":"J. Laryngol. Otol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000441122","article-title":"Dysphonia after bevacizumab rechallenge: a case report","volume":"8","author":"Carter","year":"2015","journal-title":"Case Rep. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00280-007-0453-4","article-title":"Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine","volume":"61","author":"Choi","year":"2008","journal-title":"Cancer Chemother. and Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.1985.3.5.613","article-title":"Cerebellar toxicity following high-dose cytosine arabinoside","volume":"3","author":"Dworkin","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/annonc\/mdr515","article-title":"Bevacizumab-induced laryngeal necrosis","volume":"23","author":"Hartl","year":"2012","journal-title":"Ann. Oncol."},{"key":"B8","first-page":"720","article-title":"Hoarseness in adults","volume":"96","author":"House","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"B9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.5414\/CP204035","article-title":"Chemotherapy-related dysphonia: similar and differentiating features of six cases","volume":"59","author":"Iimura","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.anorl.2018.08.017","article-title":"Transient vocal fold lesion and hoarseness associated with the use of ramucirumab: case report","volume":"136","author":"Melo","year":"2019","journal-title":"Eur. Ann. Otorhi nolaryngol Head. Neck Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.1986.4.4.571","article-title":"Neurotoxicity associated with systemic high-dose cytosine arabinoside","volume":"4","author":"Nand","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/1097-0142(197910)44:4<1189::aid-cncr2820440404>3.0.co;2-o","article-title":"High dose cytosine arabinoside (HDARAC) in refractory acute leukemia","volume":"44","author":"Rudnick","year":"1979","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s10637-013-0049-2","article-title":"Dysphonia induced by anti-angiogenic compounds","volume":"32","author":"Saavedra","year":"2014","journal-title":"New Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00002018-199005010-00003","article-title":"The toxicity of cytarabine","volume":"5","author":"Stentoft","year":"1990","journal-title":"Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1518298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:40:49Z","timestamp":1737960049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1518298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":17,"alternative-id":["10.3389\/fphar.2025.1518298"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1518298","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1518298"}}